NCAM1 and central nervous system cancer: Patients with Hsp70high grade 3 glioma exhibited a significantly elevated frequency of CD3−/CD56+ NK cells (Figure 6A) compared to the Hsp70low patient group (* p < 0.05), with median CD3−/CD56+ NK cell frequencies of 15.1% versus 6.9%, respectively.